NewLimit Blog
Subscribe
Sign in
Home
Archive
About
Latest
Top
May // June 2025 – Progress Update
Therapeutic pleiotropy
Jun 23
•
Jacob C. Kimmel
12
May 2025
NewLimit raises $130 million Series B led by Kleiner Perkins alongside NFDG, Khosla Ventures, Human Capital and others
NewLimit is developing medicines to extend human healthspan through epigenetic reprogramming
May 6
•
Brian Armstrong
,
Blake Byers
,
Cathy O'Hare
, and
Jacob C. Kimmel
23
March 2025
2025 NewLimit Progress Update
Live!
Mar 22
•
Jacob C. Kimmel
6
January // February 2025 Progress Update
Therapeutic beginnings
Mar 14
•
Jacob C. Kimmel
18
January 2025
2024 Year in Review
Restoring youthful function
Jan 9
•
Jacob C. Kimmel
18
November 2024
September // October 2024 Progress Update
In chimerico reprogramming
Nov 11, 2024
•
Jacob C. Kimmel
11
September 2024
July // August 2024 Progress Update
Completing the discovery cycle
Sep 16, 2024
•
Jacob C. Kimmel
9
July 2024
May // June 2024 Update
Reversing phenotypic age
Jul 5, 2024
•
Jacob C. Kimmel
11
June 2024
Markus Grompe is joining our Scientific Advisory Board
We’re excited to announce that Markus Grompe is joining our Scientific Advisory Board to support our Metabolism program.
Jun 11, 2024
•
Jacob C. Kimmel
3
May 2024
2024 May Progress Update - Live Event!
The days are long, the years are short
May 10, 2024
•
Jacob C. Kimmel
3
March 2024
Hao Zhu has joined our Scientific Advisory Board
Alongside the launch of our therapeutic program in hepatic metabolism, we’re excited to welcome Hao to the team.
Mar 4, 2024
•
Jacob C. Kimmel
7
January // February 2024 Progress Update
Combinatorial discoveries
Mar 1, 2024
•
Jacob C. Kimmel
5
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts